8 completed, 6 recruiting, 3 active not recruiting, 2 not yet recruiting. 21 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 21 | Completed 8, Recruiting 6, Active not recruiting 3, Not yet recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 2 | Recruiting 2 |
Follow Opioid Use Disorder: new trials by email Literature Review of Opioid Use Disorder trials Research Report on Opioid Use Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Digital Treatment for Chronic Pain and Addiction in Veterans With Opioid Use Disorder Receiving Buprenorphine Integrating the Management of Pain and Addiction via Collaborative Treatment (IMPACT), Enhanced Treatment as Usual (ETAU) - Opioid Use Disorder, Chronic Pain | Phase 3 | Not yet recruiting | VA Office of Research and Development | 250 | 2026-11-02 | 2026-09-17 |
| Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial Dronabinol Capsules, Epidiolex 100 mg/mL Oral Solution, Placebo Dronabinol - Opioid Use Disorder | Phase 3 | Not yet recruiting | Montefiore Medical Center | 40 | 2026-10-01 | 2026-06-09 |
| Buprenorphine for Individuals in Jail extended-release buprenorphine (XR-B) - Opioid Use Disorder | Phase 3 | Recruiting | Friends Research Institute, Inc. | 240 | 2025-06-20 | 2026-06-04 |
| Telemedicine XR-B for Individuals in Jail Extended Release Buprenorphine - Opioid Use Disorder | Phase 3 | Active not recruiting | Friends Research Institute, Inc. | 30 | 2025-06-01 | 2026-04-24 |
| Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose Buprenorphine - Opioid Use Disorder | Phase 2 / Phase 3 | Recruiting | Rhode Island Hospital | 250 | 2025-01-06 | 2025-10-23 |
| Standard Versus High Dose ED-Initiated Buprenorphine Induction Buprenorphine - Opioid Use Disorder | Phase 3 | Recruiting | Yale University | 360 | 2024-12-06 | 2026-05-28 |
| Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3 Transcutaneous Cervical Vagal Nerve Stimulation, Sham Stimulation, [F-18]Fallypride - Withdrawal Symptoms, Opioid Use Disorder | Phase 3 | Recruiting | Emory University | 103 | 2024-02-20 | 2026-03-27 |
| Behavioral Pharmacological Examination of a Novel Buprenorphine Induction Method Among Individuals Who Use Fentanyl Naloxone Nasal Spray - Opioid Use Disorder | Phase 3 | Active not recruiting | University of Maryland, Baltimore | 3 | 2024-01-09 | 2026-07-27 |
| Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy (Patch BRIDGE) Buprenorphine Transdermal Matrix Patch, Sham patch - Opioid Use Disorder, Pregnancy Related | Phase 3 | Completed | Washington University School of Medicine | 7 | 2023-11-27 | 2026-09-10 |
| Mobile & Online-Based Interventions to Lessen Pain Empowered Relief On-Demand, Health Education - Chronic Pain, Opioid Misuse | Phase 3 | Completed | Stanford University | 234 | 2023-08-23 | 2025-12-18 |
| Treating Polysubstance Use Using a Novel Digital Technology DynamiCare Health, Methadone Treatment-As-Usual - Opioid Use, Opioid Use Disorder | Phase 3 | Active not recruiting | Friends Research Institute, Inc. | 240 | 2023-07-26 | 2026-05-19 |
| High Dose Buprenorphine (BUP) Induction in the Emergency Department (ED) High Dose Buprenorphine, Standard Buprenorphine Dose - Opioid Use Disorder | Phase 3 | Recruiting | Rutgers, The State University of New Jersey | 140 | 2023-04-06 | 2026-07-30 |
| Divided or Single Exposure (DOSE) Study Methadone (100% dose), Methadone (50% dose) - Opioid Use Disorder, Chronic Pain | Phase 2 / Phase 3 | Recruiting | University of Maryland, Baltimore | 150 | 2023-02-21 | 2026-02-03 |
| Virginia Opioid Treatment-Emergency Department SUBLOCADE - Opioid Use Disorder | Phase 3 | Withdrawn | Virginia Commonwealth University | 2021-01-01 | 2021-02-12 | |
| Virginia Opioid Overdose Treatment InitiatVE SUBLOCADE - Opioid Use Disorder | Phase 3 | Terminated | Virginia Commonwealth University | 19 | 2019-01-04 | 2022-05-05 |
| Open-Label Treatment Extension Study RBP-6000 - Opioid Use Disorder, Opioid-related Disorders | Phase 3 | Completed | Indivior Inc. | 208 | 2016-08-17 | 2018-11-29 |
| Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL Naltrexone, Placebo, Buprenorphine - Opioid Use Disorder | Phase 3 | Completed | Alkermes, Inc. | 101 | 2016-04-01 | 2019-02-12 |
| Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder CAM2038 q1w or q4w exposure to SL BPN/NX, CAM2038 q1w or q4w new to BPN treatment - Opioid Use Disorder | Phase 3 | Completed | Braeburn Pharmaceuticals | 228 | 2015-11-01 | 2020-05-15 |
| Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension) NTX/BUP, NTX/PBO-B, PBO-N/PBO-B - Opioid Use Disorder | Phase 3 | Completed | Alkermes, Inc. | 380 | 2015-08-01 | 2019-03-06 |
| Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder SUBOXONE sublingual film, RBP-6000 - Opioid Use Disorder, Opioid-related Disorders | Phase 3 | Completed | Indivior Inc. | 775 | 2015-07-27 | 2018-03-29 |
Showing 20 of 21. Sign in to see all of them.
Opioid-Related Disorders (21) · Chronic Pain (3) · Substance-Related Disorders (2) · Alcoholism (1) · Behavior, Addictive (1) · Emergencies (1) · Pregnancy Complications (1) · Substance Withdrawal Syndrome (1)
Chemically-Induced Disorders (21) · Mental Disorders (21) · Narcotic-Related Disorders (21) · Substance-Related Disorders (19) · Pathological Conditions, Signs and Symptoms (4) · Neurologic Manifestations (3) · Pain (3) · Signs and Symptoms (3) · Alcohol-Related Disorders (1) · Behavior (1) · Compulsive Behavior (1) · Disease Attributes (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Impulsive Behavior (1) · Pathologic Processes (1)
Buprenorphine (6) · Buprenorphine, Naloxone Drug Combination (2) · Sublocade (2) · Cannabidiol (1) · Dronabinol (1) · Methadone (1) · Naltrexone (1) · Solutions (1) · Therapeutics (1) · vivitrol (1)
Friends Research Institute, Inc. (3) · Alkermes, Inc. (2) · Indivior Inc. (2) · University of Maryland, Baltimore (2) · Virginia Commonwealth University (2) · Braeburn Pharmaceuticals (1) · Emory University (1) · Montefiore Medical Center (1) · Oregon Health and Science University (1) · Rhode Island Hospital (1) · Rutgers, The State University of New Jersey (1) · Stanford University (1) · VA Office of Research and Development (1) · Washington University School of Medicine (1) · Yale University (1)
United States (20) · Australia (1) · Canada (1) · Denmark (1) · Germany (1) · Hungary (1) · Sweden (1) · Taiwan (1) · United Kingdom (1)
Frederick G Moeller, MD (2) · Maria A. Sullivan, MD, PhD (2) · Cecilia Bergeria, PhD (1) · Deepika Slawek, MD, MPH, MS (1) · Denis Antoine, MD (1) · Ethan Cowan, MD, MS (1) · Gail D'Onofrio, MD, MS (1) · James D Bremner, MD (1) · Jeannie C Kelly, MD, MS (1) · Karen Alexander, Ph.D. (1) · Kathryn Hawk (1) · Kelly E Dunn, PhD, M.B.A. (1) · Michael Frost, MD (1) · Philip T Korthuis, MD, MPH (1)
PMID 34752714, PMID 35287034, PMID 37657559, PMID 28061017, PMID 29674251, PMID 31013390, PMID 32777606, PMID 35137481, PMID 38528704, PMID 39122392, PMID 39521460, PMID 40342086, PMID 40673228, PMID 41743896, PMID 42236100
2025 (1), 4UH3DA048502 (1), I01RD000376 (1), K24DA053564 (1), R01DA056045 (1), R01DA057608 (1), R34DA063987 (1), U10DA015815 (1), UG1DA015831 (1), UG3DA056891 (1)